Cytokinetics CYTK Payments to Acquire Debt Securities, Available-for-Sale
Payments to Acquire Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's payments to acquire debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's payments to acquire debt securities, available-for-sale?
- Cytokinetics (CYTK) reported payments to acquire debt securities, available-for-sale of $106.52M in Q1 2026.
- How has Cytokinetics's payments to acquire debt securities, available-for-sale changed year-over-year?
- Cytokinetics's payments to acquire debt securities, available-for-sale decreased by 33.1% year-over-year, from $159.11M to $106.52M.
- What is the long-term trend for Cytokinetics's payments to acquire debt securities, available-for-sale?
- Over 4 years (2021 to 2025), Cytokinetics's payments to acquire debt securities, available-for-sale has grown at a 19.3% compound annual growth rate (CAGR), from $525.04M to $1.06B.